卡瑞利珠单抗联合化疗治疗晚期食管癌患者临床疗效及患者生存期影响因素分析  

Study on the efficacy of carrelizumab combined with chemotherapy in the treatment of advanced esophageal cancer and ana-lyze the factors affecting the survival time of patients

作　　者：陶洪[1] 吴福道 李海英 赵祥丽 张小静[1] TAO Hong;WU Fu-dao;LI Hai-ying;ZHAO Xiang-li;ZHANG Xiao-jing(Department of Oncology,Dazhou Central Hospital,Dazhou 635000,China)

机构地区：[1]达州市中心医院肿瘤科,四川达州635000

出　　处：《临床军医杂志》2023年第8期794-797,802,共5页Clinical Journal of Medical Officers

基　　金：四川省卫生和计划生育委员会科研课题(2021HR52)。

摘　　要：目的 探讨卡瑞利珠单抗联合化疗治疗晚期食管癌的临床疗效,以及患者生存期的影响因素。方法 选取自2019年10月至2022年12月达州市中心医院收治的120例晚期食管癌患者为研究对象。根据信封法将患者分为A组和B组,每组各60例。A组实施常规化疗;B组在A组的基础上实施卡瑞利珠单抗治疗,并维持治疗至患者疾病进展。比较两组患者的临床疗效、生存情况及不良反应发生情况。采用多因素Logistic回归分析影响患者生存期的相关因素。结果 B组治疗总有效率为56.67%(34/60),高于A组的35.00%(21/60),差异有统计学意义(P<0.05)。随访15个月,B组存活率为71.67%(43/60),高于A组的46.67%(28/60),差异有统计学意义(P<0.05)。两组患者手足麻木、口腔黏膜炎、白细胞和血小板下降、恶心呕吐、腹泻、蛋白尿、肝功能异常等不良反应发生情况比较,差异无统计学意义(P>0.05)。多因素Logistic回归分析结果显示,年龄、肿瘤直径、病程、肿瘤临床病理分期、淋巴结阳性是影响患者生存期的独立危险因素(P<0.05)。结论 卡瑞利珠单抗联合化疗治疗晚期食管癌的疗效显著,年龄、肿瘤直径、病程、肿瘤临床病理分期、淋巴结阳性是影响患者生存期的独立危险因素。Objective To study the efficacy of carrelizumab combined with chemotherapy in the treatment of advanced esophageal cancer and the factors affecting the survival time of patients.Methods A total of 120 patients with advanced esophageal cancer admit-ted to Dazhou Central Hospital from October 2019 to December 2022 were selected as the study objects.According to the envelope method,the patients were divided into group A and group B,with 60 cases in each group.Group A received conventional chemothera-py.Group B was treated with carrilizumab on the basis of group A and maintained until disease progression.The clinical efficacy,sur-vival and adverse reactions were compared between the two groups.Multivariate Logistic regression was used to analyze the related fac-tors affecting the survival of patient.Results The total effective rate of group B was 56.67%(34/60),higher than that of group A(35.00%,21/60),and the difference was statistically significant(P<0.05).After 15 months of follow-up,the survival rate of group B was 71.67%(43/60),which was higher than that of group A(46.67%,28/60),the difference was statistically significant(P<0.05).There was no statistical significance in the occurrence of side effects such as hand and foot numbness,oral mucositis,leu-kocyte and platelet decline,nausea and vomiting,diarrhea,proteinuria and abnormal liver function between two groups(P>0.05).Multivariate Logistic regression analysis showed that age,tumor diameter,course of disease,TNM stage and positive lymph nodes were independent risk factors affecting the survival of patients(P<0.05).Conclusion Carrelizumab combined with chemotherapy is effec-tive in the treatment of advanced esophageal cancer.Age,tumor diameter,course of disease,TNM stage and positive lymph nodes are independent risk factors affecting the survival of patients.

关 键 词：卡瑞利珠单抗 化疗 食管癌 生存期 

分 类 号：R735.1[医药卫生—肿瘤]